EVO · Nasdaq, OTC · CIK 0001412558

Evotec SE

Evotec SE’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 15, 2026. In fiscal 2024 (year ended Dec 31, 2024) it reported revenue of EUR 797.0M and net income of -EUR 196.1M, according to its XBRL data on EDGAR. Its EDGAR record lists 0 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2024
EUR 797.0M
Net income, FY2024
-EUR 196.1M
Form 4 filings on record, past 12 months
0

Company overview

Legal name (as filed)
Evotec SE
Tickers
EVO, EVOTF
SEC Central Index Key (CIK)
0001412558
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
HAMBURG
State or country of incorporation
Germany
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#2848 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Evotec SE’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in EUR; the fiscal year is named for the calendar year in which it ends.

Revenue
EUR 500.9MFY2020EUR 618.0MFY2021EUR 751.4MFY2022EUR 781.4MFY2023EUR 797.0MFY2024
Net income
EUR 6.3MFY2020EUR 215.5MFY2021-EUR 175.7MFY2022-EUR 83.9MFY2023-EUR 196.1MFY2024
EVO annual results
ItemFY2020
ended Dec 31, 2020		FY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024
RevenueEUR 500.9MEUR 618.0MEUR 751.4MEUR 781.4MEUR 797.0M
Net incomeEUR 6.3MEUR 215.5M-EUR 175.7M-EUR 83.9M-EUR 196.1M
Diluted EPSEUR 0.04EUR 1.30-EUR 0.99-EUR 0.47-EUR 1.11
Total assetsEUR 1.5BEUR 2.2BEUR 2.3BEUR 2.3BEUR 1.9B
Cash and equivalentsEUR 422.6MEUR 699.3MEUR 231.6MEUR 237.6MEUR 302.8M

XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = CashAndCashEquivalents. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

EVO latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Apr 8, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Oct 15, 20266-KReport of a foreign private issuer· period Oct 15, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Evotec SE, by form type:

6-K ×30SCHEDULE 13D/A ×420-F ×2SCHEDULE 13G/A ×2SCHEDULE 13D ×1SCHEDULE 13G ×1
EVO recent filings
FiledFormWhat it isOriginal
Oct 15, 20266-KReport of a foreign private issuer· period Oct 15, 2026Document · Index
Oct 14, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Oct 14, 20266-KReport of a foreign private issuer· period Oct 14, 2026Document · Index
Sep 29, 20266-KReport of a foreign private issuer· period Sep 29, 2026Document · Index
Sep 9, 20266-KReport of a foreign private issuer· period Sep 9, 2026Document · Index
Aug 13, 20266-KReport of a foreign private issuer· period Aug 13, 2026Document · Index
Jul 14, 20266-KReport of a foreign private issuer· period Jul 13, 2026Document · Index
Jun 30, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Jun 17, 20266-KReport of a foreign private issuer· period Jun 17, 2026Document · Index
May 6, 20266-KReport of a foreign private issuer· period May 6, 2026Document · Index
May 1, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Apr 30, 20266-KReport of a foreign private issuer· period Apr 29, 2026Document · Index
Apr 24, 20266-KReport of a foreign private issuer· period Apr 24, 2026Document · Index
Apr 8, 20266-KReport of a foreign private issuer· period Apr 8, 2026Document · Index
Apr 8, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Apr 7, 20266-KReport of a foreign private issuer· period Apr 7, 2026Document · Index
Apr 6, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Mar 30, 2026SCHEDULE 13DActive beneficial ownership report (over 5%)Document · Index
Mar 10, 20266-KReport of a foreign private issuer· period Mar 10, 2026Document · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jan 16, 20266-KReport of a foreign private issuer· period Jan 16, 2026Document · Index
Jan 16, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jan 13, 20266-KReport of a foreign private issuer· period Jan 13, 2026Document · Index
Jan 8, 20266-KReport of a foreign private issuer· period Jan 8, 2026Document · Index
Jan 6, 20266-KReport of a foreign private issuer· period Jan 6, 2026Document · Index
Jan 2, 20266-KReport of a foreign private issuer· period Jan 2, 2026Document · Index
Jan 2, 20266-KReport of a foreign private issuer· period Jan 1, 2026Document · Index
Dec 8, 20256-KReport of a foreign private issuer· period Dec 8, 2025Document · Index
Nov 14, 2025SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Nov 6, 20256-KReport of a foreign private issuer· period Nov 6, 2025Document · Index
Nov 5, 20256-KReport of a foreign private issuer· period Nov 5, 2025Document · Index
Nov 5, 20256-KReport of a foreign private issuer· period Nov 4, 2025Document · Index
Oct 29, 2025SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Aug 13, 20256-KReport of a foreign private issuer· period Aug 13, 2025Document · Index
Jul 30, 20256-KReport of a foreign private issuer· period Jul 30, 2025Document · Index
Jul 21, 20256-KReport of a foreign private issuer· period Jul 21, 2025Document · Index
Jun 3, 20256-KReport of a foreign private issuer· period Jun 3, 2025Document · Index
May 6, 20256-KReport of a foreign private issuer· period May 6, 2025Document · Index
Apr 17, 202520-FAnnual report of a foreign private issuer· period Dec 31, 2024Document · Index
Apr 17, 20256-KReport of a foreign private issuer· period Apr 17, 2025Document · Index

Insider filing activity

0 Form 4 filings appear in Evotec SE’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001412558 and XBRL company facts. Evotec SE on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.